| HOME >> BIOLOGY >> TECHNOLOGY |
Stockholders' equity $397,267 $363,403 $316,616
(a) FY 2007 numbers have been adjusted to reflect FY 2008 presentation.
Certain direct costs have been moved to selling, general and
administrative to ensure consistency among all business segments.
PAREXEL International Corporation
Consolidated Condensed Statement of Income
(In thousands, except per share data)
Unaudited
For the nine months ended March 31,
2008 2007
Service revenue $692,114 $536,746
Reimbursement revenue 138,929 127,376
Total revenue 831,043 664,122
Costs and expenses:
Direct costs 454,316 352,406 (a)
Reimbursable out-of-pocket expenses 138,929 127,376
Selling, general and administrative 151,365 121,425 (a)
Depreciation 24,050 19,453
Amortization 3,512 2,873
Restructuring benefit (860) (74)
Total costs and expenses 771,312 623,459
Income from operations 59,731 40,663
Other income (expense) (403) 1,598
Income before income taxes 59,328 42,261
Provision for income taxes 19,149 15,369
Effective tax rate 32.3% 36.4%
Minority interest expense 577 38
Net income
'/>"/>
| SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved |